Skip to content
Back to Blog
Bio
2026-11-097 min read17

Korea's Incremental Modified Drug Criteria Revised After Four Years — MFDS Guideline Updated Oct 30, 2026 (Container Improvement Removed, Broader Non-PK Evidence, No Recognition for Simple Salt Changes): Development Planning and Evidence Design for Pharma SMEs Moving Beyond Generics

MFDS revised its incremental modified drug recognition guideline on October 30, 2026, for the first time in four years: container improvement is gone, simple salt changes are explicitly excluded, and evidence beyond PK data can now count. This guide shows pharma SMEs how to reassess ongoing projects and design their evidence.

KITIM Consulting Team

What Changed — The First Revision Since 2022

According to materials published by the Ministry of Food and Drug Safety (MFDS), a revised Guideline on the Recognition of Incremental Modified Drugs (Guideline-0987-03) was registered on October 30, 2026. It is the first revision in roughly four years, and it makes three key changes.

  • "Container improvement" removed: The eligibility language now reads "improved usefulness such as better administration route or dosing frequency, enhanced bioavailability, or reduced adverse effects." A product that only changes its container is now hard to justify.
  • Broader evidence of usefulness: Press reports say formulation improvements can now be supported by evidence beyond pharmacokinetic (PK) data. Exactly which data qualify, and to what extent, must be confirmed in the guideline text itself.
  • No recognition for simple salt changes: The guideline now states explicitly that a simple salt change lacks an inventive step and will not be recognized.
  • Why Incremental Modified Drug Status Matters

    Recognition is tied to a drug price premium. Press reports indicate the premium is expected to remain under the ongoing drug pricing reform, but this should be confirmed against the final notice.

    Press reports also say last year saw 20 incremental modified drug approvals, the most in five years, mostly new combinations and strength changes. With generic prices under growing pressure, incremental modified drugs give pharma SMEs a realistic way to reshape their portfolios.

    What to Revisit at the Planning Stage

  • Reassess projects built on salt or container changes. Under the revised guideline, their chances of recognition may have dropped sharply.
  • Set the evidence target early. Whether you aim to show convenience (fewer doses), reduced adverse effects, or better bioavailability shapes both the development path and the budget.
  • Approval and recognition are separate procedures. A product can be approved as a data-submission drug and still fail to be recognized as an incremental modified drug. Base business and pricing plans on recognition, not approval alone.
  • Designing Evidence Beyond PK

    Map evidence types to each objective

    Decide which evidence fits your objective, such as clinical outcomes, adherence data, or safety (adverse event) data, then check the guideline text for what qualifies.

    Fix comparators and endpoints up front

    At the nonclinical and clinical design stage, decide what you will compare against the existing product and which endpoints you will use. Data assembled after the fact are much weaker evidence of usefulness.

    Use MFDS pre-submission consultation

    Request a consultation before locking the design. In your question set, spell out the improvement, comparator, endpoints, and planned data package, and ask questions the agency can actually answer, such as "Would this data package demonstrate usefulness?"

    Open Issues for Co-Developed Products

    In the aceclofenac–eperisone combination case, only the contract manufacturer received incremental modified drug status and the price premium, while the commissioning company was left out, which caused controversy. Press reports say a separate reform of recognition for co-developed products is under discussion. Until that is settled, the safest course is to clearly define development contributions and data ownership and usage rights in your contract manufacturing agreements.

    Action Checklist for Pharma SMEs

  • Check ongoing projects against the revised criteria (container improvement removed, simple salt changes not recognized)
  • Recalculate development and approval budgets to include the proposed increase in data-submission drug approval fees announced on November 6
  • Explore links to government R&D programs for incremental modified drugs and formulation technology
  • KITIM supports you at every step, from incremental modified drug development strategy and evidence design under the revised guideline to government R&D proposals. If you need to check whether a current project can still be recognized, please contact the KITIM consulting team.

    Incremental Modified DrugModified Drug Recognition GuidelineMFDS Guideline RevisionData-Submission DrugsSalt ChangeBioavailabilityDrug Price PremiumPharma SME Strategy

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    ESG

    A Green Certification Is Just Paper Unless You Use It — A 2026 Guide for Climate-Tech SMEs on Choosing Between Green Technology Certification, Green Product Confirmation and Green Specialized Company Confirmation, and Using Them for Procurement, Guarantees and R&D, Amid the Revised Operating Rules and Criticism of Unverified Reduction Effects

    This guide covers the revised green certification rules and recent criticism over unverified emissions reductions. It also explains how climate-tech SMEs can choose among the three green certifications and use them for procurement, guarantees and R&D.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.